Quantum BioPharma invests in 2,000 GameStop shares

Quantum BioPharma Ltd. (NASDAQ: QNTM) purchased 2,000 shares of GameStop Corp. (NYSE: GME) as a strategic investment for its balance sheet, the company announced.

The biopharmaceutical company, which focuses on neurodegenerative disorder treatments, said the investment aligns with its efforts to combat market corruption and enhance shareholder value.

"The Quantum team and I see the extreme value in GameStop going forward and the deep value the company has with 90% cash and marketable securities on their balance sheet," said Kevin Malone, Board Advisor to Quantum BioPharma.

Quantum BioPharma has filed an amended complaint against CIBC World Markets, RBC Dominion Securities, and others seeking damages exceeding $700 million for alleged stock price manipulation through spoofing techniques between January 2020 and August 2024.

The company also completed debt settlements totaling $40,000 in June and July 2025. It issued 1,000 Class B shares at C$41.14 per share for a June 18 settlement and 680 Class B shares at C$23.85 per share for a July 9 settlement.

Malone Wealth Ventures, LLC received 30,000 shares and 60,000 restricted stock units as compensation for consulting services provided since April 22, 2025. The firm owns 829,730 Class B shares on behalf of clients, representing approximately 21.8% of the company's outstanding Class B shares as of July 20, 2025.

Quantum BioPharma is developing Lucid-MS, a treatment for multiple sclerosis, and maintains strategic investments through its subsidiary FSD Strategic Investments Inc.

You May Also Be Interested In